Potent P2Y12 inhibitors in patients with acute myocardial infarction and cardiogenic shock
In patients with AMI complicated by cardiogenic shock, the use of potent P2Y<sub>12</sub> inhibitors was associated with a lower risk of MACE compared with clopidogrel, without an increased risk of BARC type 2 or greater bleeding. The current data supports the use of potent P2Y<sub>12</sub> inhibitors in patients with AMI and cardiogenic shock, except in patients aged ≥ 75 years or receiving VA-ECMO support.
Authors
- Joo Myung Lee (ORCID: https://orcid.org/0000-0002-2178-4014)
- Ki Hong Choi (ORCID: https://orcid.org/0000-0001-7511-9581)
- Seung‐Hyuk Choi (ORCID: https://orcid.org/0000-0002-0304-6317)
- Kyeong Ho Yun (ORCID: https://orcid.org/0000-0003-4911-8854)
- Woochan Kwon (ORCID: https://orcid.org/0000-0002-3963-3142)
- Kiyuk Chang (ORCID: https://orcid.org/0000-0003-3456-8705)
- Joo-Yong Hahn
- Yisik Kim (ORCID: https://orcid.org/0000-0003-2458-5544)
- Jeong Hoon Yang (ORCID: https://orcid.org/0000-0001-8138-1367)
- Jinhwan Jo (ORCID: https://orcid.org/0000-0002-6910-5690)
- Hyun Kuk Kim (ORCID: https://orcid.org/0000-0002-4554-041X)
- Young Joon Hong (ORCID: https://orcid.org/0000-0002-1831-8004)
- Seung‐Ho Hur (ORCID: https://orcid.org/0000-0002-3895-1915)
- Hyo‐Soo Kim (ORCID: https://orcid.org/0000-0003-0847-5329)
- Junho Ha (ORCID: https://orcid.org/0000-0003-3092-3255)
- Young Bin Song (ORCID: https://orcid.org/0000-0003-3986-9152)
- Ju Han Kim (ORCID: https://orcid.org/0000-0002-3186-0770)
- Yong Hwan Park (ORCID: https://orcid.org/0000-0002-2589-9951)
- Myung‐Ho Jeong (ORCID: https://orcid.org/0000-0001-7319-8562)
- Chang‐Hwan Yoon (ORCID: https://orcid.org/0000-0001-6305-4442)
- Jin‐Yong Hwang (ORCID: https://orcid.org/0000-0002-6632-7239)
- Hyeon‐Cheol Gwon (ORCID: https://orcid.org/0000-0002-4902-5634)
- Taek Kyu Park (ORCID: https://orcid.org/0000-0003-1440-3583)
- Jin‐Ok Jeong (ORCID: https://orcid.org/0000-0003-0763-4754)
- Doosup Shin (ORCID: https://orcid.org/0000-0003-4960-5732)
- Hyun Sung Joh (ORCID: https://orcid.org/0000-0003-2020-7028)
- Jang‐Whan Bae (ORCID: https://orcid.org/0000-0003-1362-9804)
- Hun Sik Park (ORCID: https://orcid.org/0000-0001-7138-1494)
- Seung Hun Lee (ORCID: https://orcid.org/0000-0002-2337-7826)
- Chang‐Hoon Kim (ORCID: https://orcid.org/0000-0003-1238-6396)
- Young Keun Ahn
- Doo‐Il Kim (ORCID: https://orcid.org/0000-0002-3453-0427)
Institutions
- Seoul National University (KR)
- Chungbuk National University (KR)
- Samsung (South Korea) (KR)
- Kyungpook National University Hospital (KR)
- Samsung Medical Center (KR)
- Seoul National University Hospital (KR)
- Seoul National University Bundang Hospital (KR)
- Gyeongsang National University Hospital (KR)
- Chonnam National University Hospital (KR)
- St. Francis Hospital (US)
- SNUH SMG-SNU Boramae Medical Center (KR)
- Chosun University Hospital (KR)
- Inje University Haeundae Paik Hospital (KR)
- Kangbuk Samsung Hospital (KR)
- Keimyung University Dongsan Medical Center (KR)
- Jeonbuk National University Hospital (KR)
- Chungnam National University Hospital (KR)
- The Catholic University of Korea Seoul St. Mary's Hospital (KR)
- Keimyung University (KR)
- Wonkwang University (KR)
- Sungkyunkwan University (KR)
- Catholic University of Korea (KR)
Publication Details
- Journal
- Critical Care
- Published
- 2025-02-06
- DOI
- https://doi.org/10.1186/s13054-025-05277-y
- Primary Topic
- Antiplatelet Therapy and Cardiovascular Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Centers for Disease Control and Prevention
- Korea Centers for Disease Control and Prevention